Company profile

Sanofi

biopharmaceuticals · Paris, France · sanofi.com

Sanofi is a global biopharmaceutical company focused on medicines and vaccines, with a portfolio spanning immunology, neurology, oncology, rare diseases, vaccines. Its current direction emphasizes pipeline execution, launch performance, broader use of AI and digital tools across R&D, manufacturing, commercial workflows.

Strategic priorities

Pipeline and launch execution

Management says innovation is the key driver as the company becomes a fully focused, science-driven biopharma company.

Full year 2024 results said innovation will remain the key driver for launch excellence, 2025 guidance reiterated strong sales and EPS growth.

Fourth Quarter & Full Year 2024 Results

AI at scale across the value chain

Sanofi is publicly positioning AI as an operating model, not only a research tool.

The company says it is building on Expert AI, Snackable AI, Generative AI, that 20,000 Sanofians use plai every day.

Digital Transformation and Artificial Intelligence

Data driven R&D and discovery

The company is using AI, machine learning, integrated data platforms to accelerate discovery and trials.

Sanofi says AI helps with target identification, molecule design, clinical data integration, digital biomarkers, it is building scalable data platforms across R&D.

Artificial Intelligence in R&D

Partnership led innovation

Sanofi uses external partnerships to extend science, digital, platform capabilities.

Public partnerships include AI collaborations for drug development and digital data science partnerships for targets, modules, patient experience.

Digital and Data Science Partnerships

AI program

Sanofi publicly describes a multi layer AI program built around Expert AI, Snackable AI, Generative AI. It says the program supports R&D, manufacturing, supply, commercial work, including internal GenAI tools, predictive planning, AI enabled data interactions. The company also says it is pursuing responsible AI governance through RAISE and external collaborations to accelerate drug development.

Technology posture

Sanofi appears to be a cloud aware, data intensive enterprise that is pushing digitized operations, AI enabled workflows, secure third party IT dependencies.

Cloud

4/5

5/5

Data

5/5

Public filings say core functions depend on cloud based computing and third party providers, while public AI pages stress integrated data platforms, internal AI tools, responsible AI controls.

Technology vendor categories

Cloud

n/a

Data

n/a

Security

n/a

DevOps

n/a

ERP

n/a

Cited technology signals

Public, sourced evidence of the third-party technology this company uses, from careers pages, filings and press.

Sanofi announced a first-in-class AI collaboration with OpenAI and Formation Bio to build AI-powered software for drug development.

Press98% confidencesource

Sanofi says a patient experience role should leverage its existing technology stack, including Salesforce and AWS.

Careers96% confidencesource

Sanofi says an integration specialist role should use Informatica Cloud, AWS, Python, TIBCO, Salesforce technologies, Snowflake, Veeva.

Careers95% confidencesource

Sanofi says an R&D solution architect role should build data platforms using cloud-based services, especially AWS managed services.

Careers94% confidencesource

Sanofi said it has a partnership with Owkin whose AI-driven platform uses patient data from different medical centers to build models and predict treatment response.

Press93% confidencesource

Sanofi says Exscientia’s AI-based capabilities and personalized medicine platform are used in a collaboration to test drug candidates against human tissue models before clinical trials.

Press90% confidencesource

Recent developments

Sources

Get the full sourced brief on Sanofi

This is a neutral public preview. Sign in to generate your own personalized brief, with stakeholder angles, talk tracks and where your solution fits, tailored to how you sell.

Generate a full brief

Your first brief is free, no card required.

Evidence confidence 84/100. Generated 2026-07-03 from public sources.